全文获取类型
收费全文 | 1106274篇 |
免费 | 71532篇 |
国内免费 | 2270篇 |
专业分类
耳鼻咽喉 | 15454篇 |
儿科学 | 30976篇 |
妇产科学 | 28558篇 |
基础医学 | 155501篇 |
口腔科学 | 33468篇 |
临床医学 | 94525篇 |
内科学 | 213712篇 |
皮肤病学 | 23292篇 |
神经病学 | 82613篇 |
特种医学 | 46568篇 |
外国民族医学 | 184篇 |
外科学 | 178047篇 |
综合类 | 20181篇 |
现状与发展 | 6篇 |
一般理论 | 235篇 |
预防医学 | 76549篇 |
眼科学 | 25396篇 |
药学 | 85195篇 |
6篇 | |
中国医学 | 2595篇 |
肿瘤学 | 67015篇 |
出版年
2018年 | 12461篇 |
2017年 | 10890篇 |
2016年 | 10927篇 |
2015年 | 13661篇 |
2014年 | 16280篇 |
2013年 | 20847篇 |
2012年 | 33519篇 |
2011年 | 29661篇 |
2010年 | 17015篇 |
2009年 | 17991篇 |
2008年 | 26661篇 |
2007年 | 28455篇 |
2006年 | 29353篇 |
2005年 | 36139篇 |
2004年 | 36642篇 |
2003年 | 31453篇 |
2002年 | 26385篇 |
2001年 | 58238篇 |
2000年 | 58097篇 |
1999年 | 51718篇 |
1998年 | 11252篇 |
1997年 | 9773篇 |
1996年 | 9940篇 |
1995年 | 9276篇 |
1994年 | 8597篇 |
1993年 | 7833篇 |
1992年 | 41088篇 |
1991年 | 39802篇 |
1990年 | 38840篇 |
1989年 | 37696篇 |
1988年 | 34442篇 |
1987年 | 33457篇 |
1986年 | 31316篇 |
1985年 | 29635篇 |
1984年 | 20861篇 |
1983年 | 17596篇 |
1982年 | 8619篇 |
1979年 | 19105篇 |
1978年 | 12676篇 |
1977年 | 10596篇 |
1976年 | 9237篇 |
1975年 | 10866篇 |
1974年 | 13282篇 |
1973年 | 12354篇 |
1972年 | 11877篇 |
1971年 | 11378篇 |
1970年 | 10769篇 |
1969年 | 10169篇 |
1968年 | 9261篇 |
1967年 | 8498篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Hassen Lena M. Albarrak Rana A. Albahlal Reem A. Alsaqabi Dimah K. Hassen Ikhlass M. Daghestani Maha H. Alqurtas Eman M. Alkhalaf Abdulaziz T. Bedaiwi Mohammed K. Omair Mohammed A. Almaghlouth Ibrahim A. 《Quality of life research》2022,31(11):3229-3239
Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional... 相似文献
2.
目的 建立蒙药绿松石的质量标准。方法 收集不同产地绿松石,共10批。观察绿松石样品和粉末的性状并进行理化鉴别;按2020年版《中国药典》(四部)通则方法测定绿松石样品中水分、浸出物含量;采用原子吸收光谱法测定绿松石样品铜元素含量。结果 绿松石为不规则、周围带有黑石的块状物,表面蓝绿色,体重,质硬脆,难砸碎,断面呈贝壳状,蜡样光泽,粉末呈灰绿色,无臭,味淡;理化鉴别结果显示,呈铜盐反应;10批次样品中水分含量为0.41%-3.94%(SD=1.37%),浸出物含量为0.21%-0.81%(SD=0.21%),铜元素含量为3.03%-4.63%(SD=0.63%)。结论 初步拟定绿松石中水分含量不得超多5.0%、浸出物含量不得低于0.10%,铜元素含量应为2.60%-4.84%,制定的标准可用于蒙药材绿松石的质量控制。 相似文献
3.
4.
5.
Esin Benli Küçük Ercan Kaydok Kürsad Ramazan Zor Gamze Yıldırım Biçer 《Topics in stroke rehabilitation》2020,27(8):630-635
ABSTRACT Objective: Dry eye is reported to be associated with several neurological diseases. The aim of this study is to evaluate the patients with hemiplegia after stroke for dry eye and compare their results with a control group. Materials and methods: Forty-five patients with hemiplegia and 45 individuals as the control group were included in the study. Tear function tests (Schirmer and tear breakup time) and a dry eye questionnaire for dry eye symptoms (ocular surface disease index) were performed and the results of the two groups were compared. Results: Schirmer test results were significantly lower in the post-stroke hemiplegia group compared to the control group (11.3 ± 8.2 mm and 20.6 ± 11.6 mm, respectively, p < .001). Tear breakup time results were significantly lower in the post-stroke hemiplegia group compared to the control group (7.9 ± 3.1 s and 12.1 ± 4.3 s, respectively, p < .001). Ocular surface disease index scores were not significantly different between hemiplegia and control groups (21.6 ± 20.0 and 19.8 ± 13.9, respectively, p = .635). Schirmer scores lower than 10 mm (60% and 30%, p < .001) and tear breakup time results lower than 10 s (65.6% and 28.9%, p < .001) were also higher in the hemiplegia group compared to control group. Conclusion: We found lower Schirmer test and tear breakup time results and similar OSDI scores in hemiplegia patients compared to controls. Hemiplegia patients may have dry eye without typical symptoms. This should be taken into consideration in the follow-up and rehabilitation of post-stroke hemiplegia patients. 相似文献
6.
Rupa Narayan MD Traci M. Blonquist MS Ashkan Emadi MD PhD Robert P. Hasserjian MD Meghan Burke BS Christopher Lescinskas BS Donna S. Neuberg ScD Andrew M. Brunner MD Gabriela Hobbs MD Hanno Hock MD PhD Steven L. McAfee MD Yi-Bin Chen MD Eyal Attar MD Timothy A. Graubert MD Christina Bertoli MSN Jenna A. Moran MSN Meghan K. Bergeron MSN Julia E. Foster MSN Aura Y. Ramos BSN Tina T. Som BSN Megan K. Vartanian BSN RN Jennifer L. Story LPN Kristin McGregor MS Molly Macrae BS Tanya Behnan BS Margaret C. Wey PhD Jessica Rae BSN Frederic I. Preffer PhD Patricia Lesho BA Vu H. Duong MD Mason L. Mann BA Karen K. Ballen MD Christine Connolly BS Philip C. Amrein MD Amir T. Fathi MD 《Cancer》2020,126(6):1264-1273
7.
Brittney H. Cotta Margaret F. Meagher Aaron Bradshaw Stephen T. Ryan Gerant Rivera-Sanfeliz 《Expert review of anticancer therapy》2019,19(4):301-308
Introduction: Percutaneous renal mass biopsy has evolved over the last decade with improvements on previous pitfalls including low tissue yield, high non-diagnostic rates, and complications. As understanding of tumor biology and natural history of renal cortical neoplasms has improved, percutaneous renal mass biopsy is poised to have an expanding role in an area characterized by individualized management and refined risk stratification.
Areas covered: This review summarizes the evolution of renal mass biopsy to its current state with respect to outcomes, indications, and clinical guidelines.
Expert opinion: With improved understanding of differential biological potential of renal cortical neoplasms combined with technical improvements in diagnostic yield and accuracy, utilization of renal mass biopsy is becoming an important adjunct to patient care in a broad range of clinical scenarios, including active surveillance, thermal ablation, and use of primary systemic therapy in localized and advanced settings. 相似文献
8.
9.
10.